CN EN

news

Beijing, February 6th, 2024 – The technical services of BioDuro-Sundia FTE team of Chemistry Department were once again recognized by its partners. StoneWise representatives Guanglong Sun, Director of Medicinal Chemistry, Lei Shi, Director of Chemical Synthesis, and Rena Wang, Manager of Chemical Synthesis, visited BioDuro-Sundia R&D Center in Beijing to present the FTE team with the "2023 Best Contributing Team Award". BioDuro-Sundia representatives Dr. Ning Shao, Vice President of Chemistry, Zhiwei Zhang, Associate Director of Chemistry, and Shasha Wu, Chemistry Team Leader, received this valued award from StoneWise.

StoneWise is a technology company dedicated to driving faster and better drug discovery using artificial intelligence. StoneWise aims to use AI technology and innovation to bring new perspectives to pharmaceutical industry and have created a world-leading AI platform for drug discovery. With well-proven business model, solid technology foundation and diversified team, StoneWise has set up extensive collaborations with leading institutions and pharmaceutical companies, And widely recognized by a number of top investors in AI and medicine field.

StoneWise appreciated the consistently efficient and rapid problem solving capability of BioDuro-Sundia chemistry team. Guanglong Sun, Director of Medicinal Chemistry at StoneWise, said, “BioDuro-Sundia has demonstrated excellent team synergy, efficiency and communication skills, helping us quickly find ideal candidate compounds. The work of the FTE team has impressed us, not only with their technical expertise, but also with their collaboration and problem-solving skills, and I am confident in our future cooperation!” 

Dr. Ning Shao, Vice President of Chemistry at BioDuro-Sundia, said, “We are very grateful to receive StoneWise’s recognition and trust, and we look forward to StoneWise  pipeline moving forward efficiently. BioDuro-Sundia will continue to support the success of StoneWise’s new drug development, by offering high quality and efficient technical services.” 

BioDuro-Sundia’s commitment is to provide global biopharmaceutical companies with a complete one-stop service platform to support their efforts from target identification to drug product manufacturing. Equipped with advanced research facilities and a team of more than 1,200 professional chemists, the BioDuro-Sundia Chemistry Department has provided drug R&D services for more than 330 pharmaceutical companies around the world, including many of the world's top 20 pharmaceutical companies and advanced biotechnology startups. Looking ahead, BioDuro-Sundia takes a quality-first approach and treats each program with care. BioDuro-Sundia will continue investing in Chemistry capabilities and move forward with partners together.

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 28 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with nearly 3,000 employees and 7 global sites across 6 cities.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines. For more information, please visit www.bioduro-sundia.com.

Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
0.156932s
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all